MediciNova Announces Initiation of Master Virus Seed Stock Production for its Intranasal COVID-19 Vaccine using BC-PIV Vector TechnologyGlobeNewsWire • 11/24/20
MediciNova Announces Presentation of Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model at The Liver Meeting Digital Experience™ 2020GlobeNewsWire • 11/13/20
MediciNova, in Collaboration with the University of Sydney and the Australasian Gastro-Intestinal Trials Group, Announces Plans for a Multi-center, Phase 2b Study to Evaluate MN-166 (ibudilast) in Chemotherapy-Induced Peripheral NeuropathyGlobeNewsWire • 10/22/20
MediciNova Appoints Carolyn Beaver to its Board of Directors and as Audit Committee ChairGlobeNewsWire • 10/21/20
MediciNova Announces Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model to be Presented at The Liver Meeting Digital Experience™ 2020GlobeNewsWire • 10/13/20
MediciNova Announces Positive Clinical Results Regarding MN-166 (ibudilast) for Prevention of Chemotherapy-induced Peripheral Neuropathy Published in Cancer Chemotherapy and PharmacologyGlobeNewsWire • 09/24/20
MediciNova Announces that its Intranasal COVID-19 Vaccine Successfully Induced Systemic IgG and Mucosal IgA Neutralizing Antibodies Against SARS-CoV-2 in Mice using BC-PIV Vector TechnologyGlobeNewsWire • 09/23/20
MediciNova Announces that BioComo’s Intranasal RS Virus Vaccine Successfully Induced Neutralizing Antibodies against the RS Virus in Mice using BC-PIV TechnologyGlobeNewsWire • 09/11/20
MediciNova Announces Development Progress on Intranasal Formulation of SARS-CoV-2 Vaccine for COVID-19GlobeNewsWire • 09/01/20
MediciNova Announces the Presentation of Positive Results from Phase 2 Trial of MN‑166 (ibudilast) in Alcohol Use Disorder at the American Psychological Association 2020 Annual ConventionGlobeNewsWire • 08/06/20
MediciNova to Participate in the Morgan Stanley Virtual 18th Annual Global Healthcare ConferenceGlobeNewsWire • 08/04/20
MediciNova Announces SARS-CoV-2 Vaccine Joint Development with BioComo and Mie University JapanGlobeNewsWire • 07/27/20
MediciNova to Participate in Panel Discussion at the B. Riley FBR Virtual Infectious Disease SummitGlobeNewsWire • 07/20/20
MediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) for Prevention of Acute Respiratory Distress Syndrome in Patients with COVID-19GlobeNewsWire • 07/01/20
MediciNova Announces Positive Preclinical Results Regarding MN-166 (ibudilast) in Glioblastoma (GBM) Published in Frontiers in ImmunologyGlobeNewsWire • 06/25/20
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in EuropeGlobeNewsWire • 06/23/20
MediciNova Receives Notice of Allowance for Second Patent Covering MN-166 (ibudilast) for the Treatment of GlioblastomaGlobeNewsWire • 04/20/20
MediciNova Announces Plans to Initiate a Clinical Trial of MN-166 (ibudilast) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)GlobeNewsWire • 04/08/20
MediciNova Announces Plans to Develop MN-166 (ibudilast) for Severe Pneumonia and Acute Respiratory Distress Syndrome (ARDS)GlobeNewsWire • 03/09/20
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in JapanGlobeNewsWire • 02/17/20
MediciNova Receives Notice of Intention to Grant for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in EuropeGlobeNewsWire • 01/27/20